Roivant Sciences Ltd. (ROIV) Misses Q2 EPS by 4c

Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q2 EPS of ($0.42), $0.04 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $12.53 million versus the consensus estimate of $5.7 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)
• Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.